1. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145-154. doi:10.1016/S1474-4422(18)30405‑8
  2. Isaacson SH, Pagan FL, Lew MF, Pahwa R. Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier? Clin Park Relat Disord. 2022;7:100161. doi:10.1016/j.prdoa.2022.100161
  3. Safirstein BE, Ellenbogen A, Zhao P, Henney HR 3rd, Kegler-Ebo DM, Oh C. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson's disease. Clin Ther. 2020;42(6):1034-1046. doi:10.1016/j.clinthera.2020.04.004
  4. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015;14(6):625-639. doi:10.1016/S1474-4422(15)00007‑1
  5. Thach A, Sutphin J, Coulter J, Leach C, Pappert E, Mansfield C. Patient preferences for treating “OFF” episodes in Parkinson's disease: a discrete choice experiment. Patient Prefer Adherence. 2021;15:1187-1196. doi:10.2147/PPA.S301644
  6. Fabbri M, Barbosa R, Rascol O. Off-time treatment options for Parkinson's disease. Neurol Ther. 2023;12(2):391-424. doi:10.1007/s40120-022-00435‑8
  7. López IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in Parkinson's disease: ten year follow-up study. Mov Disord. 2010;25(16):2735-2739. doi:10.1002/mds.23219
  8. Thach A, Sutphin JN, Coulter JR, Mansfield CA. Patient experiences and preferences for specific on-demand treatments for Parkinson's disease–related “OFF” episodes [abstract]. J Manag Care Pharm. 2020;26(suppl):S40. doi:10.18553/jmcp.2020.26.4‑a.s1
  9. Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A. Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States. BMC Neurol. 2021;21(1):46. doi:10.1186/s12883-021-02074‑2
  10. Subramanian I, Farahnik J, Mischley LK. Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. NPJ Parkinsons Dis. 2020;6:28. doi:10.1038/s41531-020-00128‑9
  11. Hammarlund CS, Westergren A, Åström I, Edberg AK, Hagell P. The impact of living with Parkinson’s disease: balancing within a web of needs and demands. Parkinsons Dis. 2018;2018:1-8. doi:10.1155/2018/4598651
  12. Soleimani MA, Negarandeh R, Bastani F, Greysen R. Disrupted social connectedness in people with Parkinson's disease. Br J Community Nurs. 2014;19(3):136-141. doi:10.12968/bjcn.2014.19.3.136
  13. Contreras A, Grandas F. Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients. Parkinsons Dis. 2012;2012:362572. doi:10.1155/2012/362572
  14. Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson's disease patients: opportunities and choices. Postgrad Med. 2021;133(7):721-727. doi:10.1080/00325481.2021.1936087
  15. Armstrong MJ, Rastgardani T, Gagliardi AR, Marras C. The experience of off periods: qualitative analysis of interviews with persons with Parkinson's disease and carepartners. Clin Park Relat Disord. 2019;1:31-36. doi:10.1016/j.prdoa.2019.07.008
  16. Suttrup I, Suttrup J, Suntrup-Krueger S, et al. Esophageal dysfunction in different stages of Parkinson's disease. Neurogastroenterol Motil. 2017;29(1):e12915. doi:10.1111/nmo.12915
  17. Labeit B, Berkovich E, Claus I, et al. Dysphagia for medication in Parkinson's disease. NPJ Parkinsons Dis. 2022;8(1):156. doi:10.1038/s41531-022-00421-9
  18. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006;29(2):61-67. doi:10.1097/00002826-200603000‑00001
  19. Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(5):535-540. doi:10.1016/j.parkreldis.2014.02.019
  20. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 1986;20(2):258-262. doi:10.1002/ana.410200212
  21. INBRIJA. Prescribing information. Merz Pharmaceuticals, LLC; 2022.
  22. Data on file. Merz Pharmaceuticals, LLC.
  23. Farbman ES, Waters CH, LeWitt PA, et al. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism Relat Disord. 2020;81:144-150. doi:10.1016/j.parkreldis.2020.10.029
  24. Hauser RA, Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism Relat Disord. 2019;64:175-180. doi:10.1016/j.parkreldis.2019.03.026
  25. Magrinelli F, Picelli A, Tocco P, et al. Pathophysiology of motor dysfunction in Parkinson's disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis. 2016;2016:9832839. doi:10.1155/2016/9832839